Zi FM - Search Results

1

Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.

Zi FM, Ye LL, Zheng JF, Cheng J, Wang QM. Zi FM, et al. Medicine (Baltimore). 2021 May 14;100(19):e25786. doi: 10.1097/MD.0000000000025786. Medicine (Baltimore). 2021. PMID: 34106613 Free PMC article.

2

I‑BET151 inhibits osteoclastogenesis via the RANKL signaling pathway in RAW264.7 macrophages.

Cheng J, Zheng J, Guo N, Zi F. Cheng J, et al. Mol Med Rep. 2017 Dec;16(6):8406-8412. doi: 10.3892/mmr.2017.7631. Epub 2017 Sep 26. Mol Med Rep. 2017. PMID: 28983590

3

I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma.

Guo NH, Zheng JF, Zi FM, Cheng J. Guo NH, et al. Among authors: zi fm. Biosci Rep. 2019 May 14;39(5):BSR20181245. doi: 10.1042/BSR20181245. Print 2019 May 31. Biosci Rep. 2019. PMID: 30455393 Free PMC article.

4

The potential therapeutic benefit of resveratrol on Th17/Treg imbalance in immune thrombocytopenic purpura.

Guo NH, Fu X, Zi FM, Song Y, Wang S, Cheng J. Guo NH, et al. Among authors: zi fm. Int Immunopharmacol. 2019 Aug;73:181-192. doi: 10.1016/j.intimp.2019.04.061. Epub 2019 May 16. Int Immunopharmacol. 2019. PMID: 31102993

5

Ibrutinib in CLL/SLL: From bench to bedside (Review).

Zi F, Yu L, Shi Q, Tang A, Cheng J. Zi F, et al. Oncol Rep. 2019 Dec;42(6):2213-2227. doi: 10.3892/or.2019.7364. Epub 2019 Oct 10. Oncol Rep. 2019. PMID: 31638169 Review.

6

Long Noncoding RNA H19 Promotes Tumorigenesis of Multiple Myeloma by Activating BRD4 Signaling by Targeting MicroRNA 152-3p.

Zheng JF, Guo NH, Zi FM, Cheng J. Zheng JF, et al. Among authors: zi fm. Mol Cell Biol. 2020 Jan 16;40(3):e00382-19. doi: 10.1128/MCB.00382-19. Print 2020 Jan 16. Mol Cell Biol. 2020. PMID: 31712391 Free PMC article.

7

A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells.

Wang Q, He F, He W, Huang Y, Zeng J, Zi F, Zheng J, Fei Y, Xu J, Song Y, Ye X, Lai R, Ye L, Zhu B. Wang Q, et al. Cell Immunol. 2021 May;363:104342. doi: 10.1016/j.cellimm.2021.104342. Epub 2021 Mar 14. Cell Immunol. 2021. PMID: 33765541 Free article.

8

Abnormal expression pattern of lncRNA H19 participates in multiple myeloma bone disease by unbalancing osteogenesis and osteolysis.

Guo N, Song Y, Zi F, Zheng J, Cheng J. Guo N, et al. Int Immunopharmacol. 2023 Jun;119:110058. doi: 10.1016/j.intimp.2023.110058. Epub 2023 Apr 13. Int Immunopharmacol. 2023. PMID: 37058751

9

lncRNA H19 plays a role in multiple myeloma via interacting with hnRNPA2B1 to stabilize BET proteins by targeting osteoclasts and osteoblasts.

Song Y, Guo N, Zi F, Zheng J, Cheng J. Song Y, et al. Int Immunopharmacol. 2024 Dec 5;142(Pt B):113080. doi: 10.1016/j.intimp.2024.113080. Epub 2024 Sep 16. Int Immunopharmacol. 2024. PMID: 39288624

10

Expression and role of fibroblast activation protein α in acute myeloid leukemia.

Mei S, Zhang Y, Yu L, Chen G, Zi F. Mei S, et al. Oncol Rep. 2021 Feb;45(2):641-651. doi: 10.3892/or.2020.7874. Epub 2020 Nov 30. Oncol Rep. 2021. PMID: 33416165 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters